Qingsong Health's stock surged 7.27% during intraday trading, rebounding from previous declines as the company announced significant progress in its artificial intelligence medical initiatives.

The healthcare company revealed that its self-developed evidence-based medical AI agent "Zhengyuanfang" has entered over 100 key hospitals nationwide, marking the product's transition into large-scale commercial deployment across nursing management, clinical assistance, and hospital administration scenarios.

Additionally, the AI agent successfully passed the MedClaw evaluation by China Academy of Information and Communications Technology, becoming the first medical health intelligent assistant to receive this certification. The company stated it will continue advancing its "AI + full-chain health services" strategy, pushing multi-scenario applications across hospital, physician, and health service platforms.